Eli Lilly Stock Could Rise 30% on Business Model Shift

According to an analysis from Trefis, Eli Lilly (LLY) stock may be undervalued by as much as 30%, driven by a structural shift in its business model that the broader market is currently overlooking. The analysis comes as the stock faces a valuation penalty following early prescription data favoring Novo Nordisk's oral therapy.

Recommendation Change

The analysis does not specify a before/after recommendation, but suggests the market is mispricing Lilly's fundamental business transformation.

Analyst's Rationale

The analyst highlights the central debate between high demand for Lilly's products and pricing pressure from pharmacy benefit managers (PBMs). While early volume data favors the competitor (Novo Nordisk) due to its established brand, the structural shift in Lilly's business model — though not detailed in the analysis — could be the key value driver.

Context

This analysis comes amid increasing regulatory and pricing pressures in the pharmaceutical sector. Lilly's stock recently declined after Novo Nordisk's oral therapy prescription data showed better-than-expected performance. Other analysts may have differing views, but this analysis argues the market overreacted to competitive threats.

What to Make of It

While the analysis points to a 30% upside opportunity, investors should consider risks from pricing pressures and competition. The investment decision hinges on one's assessment of Lilly's ability to execute the mentioned structural shift.